ABCSG 67N / CAROLEEN Overview
A non-interventional study for ribociclib in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer at high risk of recurrence to evaluate real-world effectiveness, safety profile, patient compliance and quality of life
| Study start: | global Q1/2025 national Q4/2025 |
| Coordinating Investigator: | Christian Singer, Austria |
| Planned Participants: | 3250 (Austria, Germany) |
| Study Design : (Click to enlarge) |
 |
Share on